ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications
March 27 2017 - 7:00AM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company
focused on new immunotherapies, today announced the appointment of
Amy Trevvett as Vice President of Investor Relations and Corporate
Communications.
“Amy’s background in investor relations and
corporate communications in the life sciences industry is an ideal
fit for ZIOPHARM, and we look forward to her contributions as a
member of our leadership team,” said Caesar J. Belbel, Executive
Vice President, Chief Operating Officer and Chief Legal Officer of
ZIOPHARM. “As part of our focus on communications with our
shareholders and the investment community, we will be hosting
quarterly conference calls beginning this May, in conjunction with
our first quarter 2017 earnings report. We look forward to sharing
our progress throughout this year and beyond, as our multiple
immunotherapy platforms continue to move forward into and through
clinical development.”
Ms. Trevvett brings to ZIOPHARM more than 15
years of experience in a range of investor relations and corporate
communications roles at publicly traded biotechnology and medical
device companies. Most recently, she served as Director of Investor
Relations and Corporate Communications at HeartWare International,
Inc., a leading innovator of less-invasive, miniaturized
circulatory support technologies for advanced heart failure, which
was acquired by Medtronic plc. Prior to HeartWare, Ms. Trevvett
served in communications and investor relations roles at both
Alkermes, Inc., a global biopharmaceutical company developing
innovative medicines for the treatment of central nervous system
(CNS) diseases, and Sepracor, Inc. (now Sunovion Pharmaceuticals),
a leader in CNS and respiratory therapies. She holds a bachelor of
arts from Dickinson College.
About ZIOPHARM Oncology,
Inc.:
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing novel gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer and graft-versus-host-disease. The Company's
immuno-oncology programs, in collaboration with Intrexon
Corporation (NYSE:XON) and the MD Anderson Cancer Center, include
chimeric antigen receptor T cell (CAR-T) and other adoptive
cell-based approaches that use non-viral gene transfer methods for
broad scalability. The Company is advancing programs in multiple
stages of development together with Intrexon Corporation's
RheoSwitch Therapeutic System® technology, a switch to turn on and
off, and precisely modulate, gene expression in order to improve
therapeutic index. The Company's pipeline includes a number of
cell-based therapeutics in both clinical and preclinical testing
which are focused on hematologic and solid tumor malignancies.
Forward-Looking Safe-Harbor
Statement:
This press release contains certain
forward-looking information about ZIOPHARM Oncology, Inc. that is
intended to be covered by the safe harbor for "forward-looking
statements" provided by the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company's plans and
expectations regarding its securities offerings, fundraising
activities and financial strategy, the progress, timing and results
of preclinical and clinical trials involving the Company's drug
candidates, and the progress of the Company's research and
development programs. All of such statements are subject to certain
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of the Company, that could cause
actual results to differ materially from those expressed in, or
implied by, the forward-looking statements. These risks and
uncertainties include, but are not limited to: our ability to
finance our operations and business initiatives and obtain funding
for such activities, whether chimeric antigen receptor T cell
(CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies,
or any of our other therapeutic candidates will advance further in
the preclinical or clinical trials process and whether and when, if
at all, they will receive final approval from the U.S. Food and
Drug Administration or equivalent foreign regulatory agencies and
for which indications; whether chimeric antigen receptor T cell
(CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies,
and our other therapeutic products will be successfully marketed if
approved; the strength and enforceability of our intellectual
property rights; competition from other pharmaceutical and
biotechnology companies; and the other risk factors contained in
our periodic and interim reports filed from time to time with the
Securities and Exchange Commission, including but not limited to,
our Annual Report on Form 10-K for the fiscal year ended December
31, 2016. Readers are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date
hereof, and we do not undertake any obligation to revise and
disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of or non-occurrence of any events.
TrademarksRheoSwitch
Therapeutic System® and RTS® are registered trademarks of Intrexon
Corporation.
Contact:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024